Sponsored Links 
Durect Corporation - DRRX
We are staying positive on Durect Corp. (DRRX - Snapshot Report) despite some recent setback and future challenges. Our investment thesis is based on the fact that we believe Remoxy will eventually receive approval in the U.S., and that management will secure another, potentially more lucrative, partnership on TRANSDUR-Sufentanil.
We are also optimistic on Posidur and believe that management will look to secure a partnership in the U.S. and Japan in 2009 or 2010. Finally, we are comfortable with the cash position given the current $42 million balance and all partnering opportunities available to management.
We continue to recommend investors Buy the stock. Our target remains $5 per share.
Durect Corporation - DRRX : FULL ANALYST REPORT
|
 |
 |
 Share |
 RSS |
 Rate Pos |
 Rate Neg |
 Comment |
|
|
||||||
Free Stock Analysis From Zacks
Includes Zacks Long-Term Recommendation and Target Price
Loading Stories...Related Content
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
- Free Four Zacks #1 Rank "Strong Buy" Stocks
- Free Timely Market Commentary
- Free Wealth Management Tips
- Free Profitable Strategy Screens
- Free Bull and Bear Stocks of the Day
Zacks FREE Registration
X Close
Loading Stories...Most Popular on Zacks.com
-2.49 %
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Feb 10, 2010 09:59 am ET |
[CLICK TO CLOSE X]